XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Income (loss) from continuing operations $ 5,959 $ (3,413)
Accretion of Series A redeemable convertible preferred stock (230)
Undistributed earnings from continuing operations allocated to participating securities (830)
Net income (loss) from continuing operations attributable to common stockholders - basic 4,899 (3,413)
Add: undistributed earnings from continuing operations allocated to participating securities 830
Reallocation of undistributed earnings from continuing operations to participating securities (829)
Net income (loss) from continuing operations attributable to common stockholders - diluted 4,900 (3,413)
Net loss from discontinued operations attributable to Oncocyte Corporation (2,926) (6,878)
Undistributed losses from discontinued operations allocated to participating securities 424
Net loss from discontinued operations attributable to common stockholders - basic (2,502) (6,878)
Add: undistributed losses from discontinued operations allocated to participating securities (424)
Reallocation of undistributed losses from discontinued operations to participating securities 424
Net loss from discontinued operations attributable to common stockholders - diluted (2,502) (6,878)
Net income (loss) attributable to common stockholders - basic 2,397 (10,291)
Add: undistributed earnings allocated to participating securities 406
Reallocation of undistributed earnings to participating securities (405)
Net income (loss) attributable to common stockholders - diluted $ 2,398 $ (10,291)
Weighted average common shares outstanding - basic 119,150 92,243
Restricted stock units 103
Weighted average common shares outstanding - diluted 119,253 92,243
Net income (loss) from continuing operations attributable to common stockholders per share - basic $ 0.04 $ (0.04)
Net loss from discontinued operations attributable to common stockholders per share - basic (0.02) (0.07)
Net income (loss) attributable to common stockholders per share - basic 0.02 (0.11)
Net income (loss) from continuing operations attributable to common stockholders per share - diluted 0.04 (0.04)
Net loss from discontinuing operations attributable to common stockholders per share - diluted (0.02) (0.07)
Net income (loss) attributable to common stockholders per share - diluted $ 0.02 $ (0.11)
Total $ 12,818 $ 8,984
Equity Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 12,352 7,125
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 216 85
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total $ 250 $ 1,789